Cerebrolysin

FPF 1070, Cerebrolysatum, porcine brain hydrolysate

Checked Oct 28, 2026

The short answer

Human-trial signal for memory, focus and brain fog in healthy adults

Grade B for memory and focus in healthy adults, result mixed: the one randomized trial, 48 healthy men in 1998, found EEG changes and only a non-significant memory trend.

Approved?: Approved outside the US for (not FDA-approved): supportive treatment of cerebrovascular disorders, including Alzheimer-type and vascular dementia, post-stroke deficits and head injury (Austria, BASG registration 1-21380, authorised 1996; label dated March 2021).
Safety: C, thinly characterized: Dizziness, headache and injection-site reactions are common, seizure frequency may rise in epilepsy, and the 2023 Cochrane stroke review found more non-fatal serious adverse events (RR 2.39), though not more deaths or total serious events.

Do we take it? Our read

Here's the deal with Cerebrolysin. It has actual clinical trials, which puts it ahead of 90% of the peptides people are injecting, but the bar is lower than it looks. The stroke meta-analysis showed 1.39 points on the NIHSS, and the NINDS says you need 4+ for clinical meaningfulness. The functional independence endpoint flat-out did not reach significance. The nootropic community is self-injecting this stuff for healthy-brain cognitive enhancement with zero human evidence, stacking it with racetams, and attributing the result to the vial when it could be anything. What's actually gnarly is that the guy who built most of the preclinical mechanistic case was committing data fraud for decades while being funded by the manufacturer. That's not a footnote, that's a foundational crack. If you have a real neurological injury and a physician in the loop, the data is at least real. If you're healthy and injecting it for focus, the honest answer is that nobody knows.

The full answer: what it is for, the dose, the units

What people take it for: People take it for memory, focus and brain fog, and doctors in Austria and many other countries use it after stroke, brain injury and in dementia. It is a porcine brain-tissue extract given by IV infusion or injection.

Does it work for memory, focus and brain fog in healthy adults? B, human-trial signal. Result: mixed.

Grade B for memory and focus in healthy adults, result mixed: the one randomized trial, 48 healthy men in 1998, found EEG changes and only a non-significant memory trend. For stroke and brain injury it is grade A with mixed results, and approved in Austria for those uses.

Approved outside the US for (not FDA-approved): supportive treatment of cerebrovascular disorders, including Alzheimer-type and vascular dementia, post-stroke deficits and head injury (Austria, BASG registration 1-21380, authorised 1996; label dated March 2021). That does not carry over to memory, focus or brain fog in healthy adults, and it is not approved by the FDA for any use. Cerebrolysin Fachinformation (Austrian SmPC), BASG medicines register, section 4.1

Highest evidence for any use: A for recovery after stroke and traumatic brain injury, and vascular dementia.

Safety: C, thinly characterized. Dizziness, headache and injection-site reactions are common, seizure frequency may rise in epilepsy, and the 2023 Cochrane stroke review found more non-fatal serious adverse events (RR 2.39), though not more deaths or total serious events.

Do not use if: The Austrian label lists hypersensitivity, status epilepticus and severe renal impairment as contraindications, and advises caution in allergic diathesis, epilepsy and grand mal seizures because seizure frequency may rise.

Could it be placebo? For healthy-adult memory and focus, the one small randomized trial showed no significant memory effect over placebo, and self-reported benefits have no controlled data, so a placebo effect cannot be ruled out; in stroke and brain-injury trials, results beat placebo on some scales and not others.

The dose people use, and the units to draw

The Austrian label gives 20 to 50 mL a day by IV infusion for 10 to 21 days in ischemic stroke and 10 to 30 mL a day in dementia; no verified dose statement from a named non-seller source exists for healthy-user courses.

Source	Dose	How often and how	Who it was for	Link
Austrian SmPC (BASG 1-21380)	20 to 50 mL per day	Intravenous infusion for 10 to 21 days	Adults with ischemic stroke	Section 4.2, daily-dose table
Austrian SmPC (BASG 1-21380)	30 to 50 mL per day	Intravenous infusion for 10 to 21 days	Adults with hemorrhagic stroke	Section 4.2, daily-dose table
Austrian SmPC (BASG 1-21380)	20 to 50 mL per day	For 7 to 30 days	Adults with traumatic brain injury (commotio and contusio)	Section 4.2, daily-dose table
Austrian SmPC (BASG 1-21380)	10 to 30 mL per day	Treatment cycle of 4 weeks at 5 applications per week; cycles may be repeated after 2 months, and from the second cycle given 2 to 3 times a week	Adults with Alzheimer-type or vascular dementia	Section 4.2, daily-dose table and text below it
Austrian SmPC (BASG 1-21380)	Up to 5 mL intramuscular; up to 10 mL intravenous; infusion recommended from 10 mL	Volumes from 10 mL diluted in 0.9% saline, Ringer or 5% glucose and infused slowly over about 15 to 60 minutes	Per-injection ceilings for all labelled uses; the label does not recommend use under 18	Section 4.2, Art der Anwendung
CASTA trial, Heiss et al., Stroke 2012	30 mL per day	Intravenous infusion for 10 days, added to aspirin 100 mg daily	1,070 adults with acute ischemic hemispheric stroke, randomized within 12 hours; the primary endpoint showed no significant difference from placebo	Abstract, Methods
Cochrane review of Cerebrolysin in acute ischaemic stroke, Ziganshina et al. 2023	10 to 50 mL per day across included trials	Intravenous; 30 mL per day for 10 days in four trials (Amiri Nikpour 2014, CASTA, CERE-LYSE-1, Xue 2016), 50 mL per day for 21 days (Ladurner 2005), 10 or 50 mL per day for 10 days in the two arms of Skvortsova 2004	7 randomized trials, 1,773 participants with acute ischaemic stroke	Included-studies dose descriptions
CAPTAIN I, Poon et al., Neurol Sci 2020	50 mL per day, then 10 mL per day	Cerebrolysin or saline daily for 10 days at 50 mL, then two further 10-day cycles at 10 mL per day, added to standard care	46 adults with moderate-to-severe traumatic brain injury; the primary multivariate endpoint just missed significance in the intention-to-treat analysis	Abstract, Methods
CAPTAIN II, Muresanu et al., Neurol Sci 2020	50 mL per day, then 10 mL per day	Cerebrolysin or saline daily for 10 days at 50 mL, then two further 10-day cycles at 10 mL per day, added to standard care	142 enrolled adults (139 analysed) with moderate-to-severe traumatic brain injury; the primary ensemble was significant at day 90	Abstract, Methods
Funke et al., J Neural Transm Suppl 1998 (healthy volunteers)	10 mL, 30 mL or 50 mL per day (three arms)	Infusion in 100 mL saline for 10 days versus 100 mL saline placebo	48 healthy men; EEG changes in the 10 mL group and only a non-significant trend on word recall; mild signs of overdosage and a small blood-pressure drop at the highest dose	Abstract
Huberman Lab with Dr. Craig Koniver, peptide and hormone therapies	No dose stated	Cerebrolysin is mentioned for brain fog and its availability; no amount, route or schedule is given. The guest runs a clinic that sells peptides, so he is not used as a dose source.	Podcast discussion, not a trial	Auto-transcript, about 1:42:29 to 1:42:53; verify by ear

For labelled uses the daily dose runs from 10 mL (dementia, low end of 10 to 30 mL) to 50 mL (stroke and brain injury), by IV infusion, per the Austrian label; trials ranged from 10 to 50 mL a day.

No named non-seller source gives a dose for healthy-user memory or focus courses, so the earlier community injection figures were removed. The ESCAS aphasia trial dose is only stated by the manufacturer, not in the abstract, so it is not listed. The Cochrane vascular dementia review says doses varied without giving them in its abstract. A small 2000 oral-dose study in healthy elderly people was left out because it is an uncontrolled before-and-after report from a lab with manufacturer ties.

Reported by the named source, never prescribed by us.

How many units do I draw?

Cerebrolysin is sold as a ready-made 215.2 mg per mL solution and is dosed in mL, not units, so no reconstitution or calculator step applies. Open the dose calculator

Why it might work

BBB penetration
Cerebrolysin is an enzymatic hydrolysa
Neurotrophic factor mimicry
Peptide fragments are proposed to mimi
Anti-apoptotic signaling
PI3K/Akt pathway activation is assumed
Microglial modulation (disputed)
Reduction of microglial activation and

Assumed pathway, not shown in people.

Assumed (mechanistic plausibility, not proven causal chain in humans). Cerebrolysin contains low-molecular-weight peptide fragments (all under 10 kDa) that are proposed to cross the blood-brain barrier and mimic endogenous neurotrophic factors including BDNF, NGF, GDNF, and CNTF. Proposed downstream effects include activation of TrkB and TrkA receptors, PI3K/Akt and MAPK/ERK pathway signaling, inhibition of caspase-3 (apoptosis), upregulation of Bcl-2 (anti-apoptotic), and reduction of microglial activation. Whether these mechanisms are operative in healthy brains at community-level doses is not established. Caution: a substantial portion of the preclinical mechanistic evidence was produced by Eliezer Masliah and Hari Shanker Sharma, both of whom have papers under active retraction and data integrity review as of 2025.

The trials, claim by claim

Letters count randomized trials whether they worked or not. For Cerebrolysin the result tags matter: the largest stroke trial (CASTA, 1,070 people) missed its primary endpoint, while CAPTAIN II in brain injury and the vascular dementia pool were positive but low certainty.

Real RCT data in stroke and TBI, but the primary functional independence endpoint did not reach significance and NIHSS improvement (1.39 points) sits below the clinically meaningful threshold.
The nootropic community uses it off-label for cognitive enhancement in healthy brains. The only randomized trial in healthy adults is a small 1998 study of 48 men that found EEG changes and a non-significant memory trend.
The preclinical mechanistic foundation has a serious problem: multiple core papers were retracted in 2025 after NIH confirmed the lead researcher (Eliezer Masliah) fabricated data, and he was funded by the manufacturer.

Improves functional recovery after acute ischemic stroke

Result: mixed

Meta-analysis of 14 RCTs (N=2,884) showed pooled NIHSS improvement of 1.39 points (95% CI 0.53-2.25). However, the primary functional independence endpoint (mRS 0-2) did NOT reach statistical significance (RR 1.31, 95% CI 0.90-1.91, p>0.05). The NIHSS minimum clinically important difference is typically defined as 4+ points by NINDS standards, so 1.39 points is sub-threshold for clinical meaningfulness at the individual level. Most trials were industry-funded. The largest single trial, CASTA (1,070 people, 30 mL a day for 10 days), missed its primary endpoint.

PMC12465088 - Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials (2025)

Improves outcomes in traumatic brain injury

Result: mixed

2023 systematic review of 10 clinical studies (N=8,749) found statistically significant improvement in GCS and GOS scores. Mortality and length of stay were not affected. Multiple industry-sponsored trials limit certainty. Important limitation: only a subset of the 10 studies were blinded RCTs; the remainder were retrospective observational studies. The pooled N reflects the mixed design, not an RCT-only sample, which makes the B grade a ceiling rather than a floor for this claim.

PMC10046100 - Cerebrolysin in TBI: Systematic Review and Meta-Analysis, Brain Sciences 2023

Benefits Alzheimer's disease and vascular dementia

Result: mixed

Cochrane review for vascular dementia (2019, 6 RCTs, N=597) found promising signals but rated evidence quality as low to very low. The 2023 Cochrane review in acute ischaemic stroke (7 RCTs, 1,773 people) found no benefit on all-cause death and a higher rate of non-fatal serious adverse events with Cerebrolysin (RR 2.39, 95% CI 1.10-5.23; 3 trials, N=1,335), larger at 30 mL for 10 days (RR 2.87, 95% CI 1.24-6.69), with no difference in total serious adverse events. The 2019 dementia review reported no difference in adverse effects, on very low-quality evidence.

Cochrane Library - Cerebrolysin for Vascular Dementia, Cui 2019 (PMID 31710397)

Reduces microglial activation and neuroinflammation

Result: not tested in humans

In vitro and animal data support anti-inflammatory and neuroprotective effects via BDNF/NGF receptor mimicry. Mechanistic plausibility is established; direct causal evidence in humans is not. Note: this study originates from the EuroEspes Biomedical Research Center (Alvarez XA, Cacabelos R, et al.), a lab with documented ties to EVER Pharma (the cerebrolysin manufacturer) and co-author networks with research integrity concerns. The study itself has not been retracted, but its institutional provenance and funder proximity should be weighed when using it as a mechanistic anchor.

PubMed 10961440 - Cerebrolysin reduces microglial activation in vivo and in vitro (Alvarez et al., EuroEspes Biomedical Research Center, 2000)

Safe with adverse event profile similar to placebo in controlled trials

Result: mixed

Meta-analysis of 12 RCTs (N=2,202) found no statistically significant difference in adverse events vs. placebo in stroke trials. However, the independent 2023 Cochrane review of stroke trials found more non-fatal serious adverse events with Cerebrolysin (RR 2.39, 95% CI 1.10-5.23; 3 trials, N=1,335; RR 2.87 at 30 mL for 10 days), so the placebo-like safety picture in stroke is contested. None of this generalizes to healthy users. The Austrian label contraindicates use in status epilepticus, hypersensitivity and severe renal impairment, and advises caution in epilepsy and grand mal seizures. Rare seizure reports exist, causality not established.

PMC8708612 - Safety Meta-Analysis 12 RCTs (stroke population only), 2021

A 2025 double-blind RCT (ESCAS, 132 enrolled) found Cerebrolysin plus speech therapy improved Western Aphasia Battery scores more than placebo plus speech therapy after stroke, with no excess adverse events; the authors call it a pilot.

Result: worked

Two-center randomized double-blind placebo-controlled pilot, Stroke 2025. Industry involvement not checked.

PubMed 39957612, ESCAS, Stroke 2025

Risks and the label warnings

Adverse events

Generally mild in acute stroke controlled trials. Most common: dizziness, agitation, feeling hot, injection site reactions, mild headache, nausea. Adverse event incidence statistically similar to placebo in stroke meta-analyses (N=2,202). Important caveat: the 2023 Cochrane review of acute ischaemic stroke trials found a statistically significant ~2.4x increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10-5.23; 3 trials, N=1,335), with the 30 mL/10-day protocol showing RR 2.87, though not in total serious adverse events or deaths.

Contraindications

The Austrian label lists hypersensitivity, status epilepticus and severe renal impairment as contraindications, and advises caution in allergic diathesis, epilepsy and grand mal seizures because seizure frequency may rise. The label does not recommend use under 18. The 2023 Cochrane stroke review documents a statistically significant increase in non-fatal serious adverse events, so stroke patients should not be assumed to carry placebo-level risk. The 2019 vascular dementia review found no adverse-effect difference, on very low-quality evidence.

Theoretical concerns

Porcine-derived proteins carry a theoretical prion contamination risk, though manufacturing processes (enzymatic hydrolysis + filtration) are designed to eliminate this. Seizure threshold lowering is a documented concern.

What nobody knows yet

Long-term effects of repeated cycling in healthy individuals are unstudied. The complex mixture contains hundreds of uncharacterized peptide fragments; batch variation between manufacturers (especially gray-market sources) is a real concern. No human pharmacokinetic data on IM vs. IV bioavailability equivalence.

What else could explain the result

Heavily stacked in nootropic communities with racetams, semax, selank, and other neuropeptides, making attribution impossible. Many users are also on TRT or GLP-1 agonists; improved cognitive clarity on either of those baselines is commonly misattributed to Cerebrolysin. Clinical trial benefits occurred in acute injury patients, not healthy individuals.

Is the vial what it says?

Cross-checked against the cited sources below. The grade reflects the absence of formal human safety and efficacy data for the intended uses. In the stroke trial the functional-independence primary endpoint (mRS) did not reach significance (RR 1.31, p>0.05), and the NIHSS gain of 1.39 points is below the NINDS minimal clinically important difference. The TBI evidence mixes randomized and observational designs. The 2023 Cochrane review of acute ischaemic stroke trials found more non-fatal serious adverse events with Cerebrolysin (RR 2.39, 95% CI 1.10-5.23; 3 trials, 1,335 people), while the vascular dementia review found no difference in adverse effects on very low-quality evidence. The microglial work carries disclosed institutional ties (EuroEspes/EVER Pharma), and the research-integrity history (Masliah/Sharma misconduct, EVER Pharma funding) is described in the risk and mechanism sections. Sources include the 2023 Cochrane ischaemic stroke update and a retraction notice.

Half-life and storage

Half-life: Not well characterized in humans. The peptide mixture is heterogeneous; individual fragments likely have half-lives ranging from minutes to a few hours. IV infusion achieves peak CNS levels during administration; IM half-life estimates are extrapolated, not directly measured.

Once mixed: Not reconstituted. Cerebrolysin is supplied as a ready-to-use aqueous solution (1 mL, 2 mL, 5 mL, 10 mL, 20 mL ampoules at 215.2 mg/mL). Requires refrigeration (2-8 degrees C). Gray-market sources may have cold-chain gaps that degrade the peptide mixture.

What I noticed, and what people report

What people report

Volume of reports: moderate. A real body of reports, fairly consistent.

High volume of community reports, primarily from Eastern European and Russian nootropic communities where Cerebrolysin is legally available and inexpensive. Growing Western nootropic interest since 2020.

Mixed. Subjective reports of improved focus, mood, and verbal fluency are common but inconsistent. A subset reports agitation, headache, and no noticeable effect. TBI/stroke recovery anecdotes tend to be more positive and consistent than healthy-user reports.

Low for healthy-user enhancement claims. The community signal reflects a drug being used far outside its studied population (acute neurological injury) at doses below clinical trials. Hard to separate from expectation effects.

Anecdote: Eastern European and Russian users report improved verbal fluency and recall after IV courses, often at clinical doses; effect described as arriving 2-3 days into the course and fading within 4-6 weeks post-cycle
Anecdote: A subset of users report agitation, irritability, and disrupted sleep during the active dosing window, especially at higher doses, consistent with the neurostimulatory profile seen in trials
Anecdote: Nootropic community users doing IM self-injection report subtler effects than IV users, with some reporting no noticeable change; the IV-vs-IM gap in perceived effect is a recurring theme
Anecdote: TBI and post-concussion users report the most consistent and pronounced subjective benefit; healthy-brain users are the most split, with a vocal minority reporting nothing and attributing prior reports to placebo

Reports are anecdote, not proof.

Can you tell if it is working?

Not trackable

No objective self-tracker exists: cerebrolysin's only human-validated efficacy readouts are clinician-administered cognitive/functional scales (ADAS-cog, NIHSS, Barthel, mRS), not any blood, urine, wearable, scan, or CGM you can run yourself.

Bloodwork

No blood proxy

Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.

Cerebrolysin is a porcine brain-derived neuropeptide mixture that acts centrally by mimicking neurotrophic factors (BDNF/NGF/GDNF/CNTF) on CNS neurons; its therapeutic action is a neurological/cognitive effect that leaves no fingerprint on any routine peripheral blood analyte.

Read this before you spend on labs

Routine bloodwork cannot confirm cerebrolysin is working. Its effect is neurological and cognitive, and in every clinical trial efficacy is measured by functional/neurorecovery scales (NIHSS, modified Rankin, Barthel Index, GOS, MMSE, ADAS-cog), not labs. The only mechanism-relevant biomarker would be a central neurotrophin like serum BDNF, which is a research-only assay, not orderable at LabCorp/Quest, and not a validated human efficacy proxy anyway. No CBC, CMP, hormone, or other standard panel analyte moves in a way that reflects the drug's biological action, so a user cannot prove response through blood. Track subjective/functional cognitive or neurorecovery outcomes instead.

Bottom line

Cerebrolysin's claimed benefit is neurological recovery and cognition, and cognition has no validated objective proxy in any consumer modality. In trials the effect is captured only by clinician-scored scales (ADAS-cog+, NIHSS, modified Rankin, Barthel, MMSE) administered in controlled settings, and even there the stroke functional-independence endpoint has not reliably reached significance. With blood tier=none, there is genuinely nothing physiologic to track: no urine metabolite, stool marker, sleep/HRV signature, glucose pattern, VO2max change, DEXA change, or gene test reflects whether it is working, and serum BDNF is research-only and non-specific, not a validated proxy. A wearable will not show it. The most honest self-test is a blinded, placebo-controlled trial-of-one using a validated computerized cognitive battery (e.g., Cambridge Brain Sciences/CANTAB) with pre/post scores, but this is effort-dependent, high-placebo-risk, not a physiologic modality, and does not constitute objective biological verification. Treat any perceived benefit as unconfirmed.

Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.

How to track it

History

First documented human use: 1954, initial clinical approval in Austria for metabolic brain failure and TBI by EVER Neuro Pharma (formerly EBEWE)

1949Developed by Professor Eberhard Windisch at the University of Vienna as a porcine brain-derived extract for treating TBI and metabolic brain failure in post-war Austria
1954First approved for clinical use in Austria; EBEWE (later EVER Neuro Pharma) industrialized production in the 1970s and standardized batch-to-batch consistency
1980s-1990sGained regulatory approval across Russia, Eastern Europe, China, and Asian nations; now approved in 45+ countries for stroke, TBI, and dementia
2019Cochrane review on vascular dementia described evidence as promising but low-certainty; FDA never approved it for any indication in the US, though orphan drug designation was granted for frontotemporal dementia investigation
2023-2025NIH found that Eliezer Masliah, former head of the Division of Neuroscience at the National Institute on Aging, committed research misconduct (data fabrication and falsification) across 130+ papers published 1997-2023. Masliah received EVER Pharma funding for multiple cerebrolysin studies and co-authored with Herbert Moessler (former EVER Pharma general manager, 19 papers flagged). Multiple cerebrolysin preclinical papers by Masliah and collaborator Hari Shanker Sharma were retracted by 2025, including a BMC Neuroscience paper on Pick's disease (retraction note PMID 40065222). The scope of affected preclinical cerebrolysin literature is actively under review as of 2025.

All sources

PMC12465088 - Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: 14 RCT Meta-Analysis (2025)(Most comprehensive stroke meta-analysis available as of 2025; pooled N=2,884; NIHSS improvement 1.39 points (significant); mRS 0-2 functional independence RR 1.31 (NOT significant, p>0.05); notes industry funding limitations. NIHSS improvement is sub-threshold for NINDS MCID of 4+ points.)
Cochrane Library - Cerebrolysin for Vascular Dementia (Cui 2019, PMID 31710397)(Cochrane systematic review; low to very low certainty overall; 6 RCTs N=597; major concerns about industry funding and study heterogeneity)
PMC10046100 - Cerebrolysin in TBI: Systematic Review and Meta-Analysis (2023)(10 clinical studies (prospective and retrospective mixed design, not all blinded RCTs) N=8,749; significant GCS/GOS improvement; mortality not affected. Mixed study design should be weighted when interpreting pooled results.)
PMC8708612 - Safety of Cerebrolysin for Ischemic Stroke: 12 RCT Meta-Analysis (2021)(Safety-focused meta-analysis N=2,202 stroke patients; adverse events not significantly different from placebo in this population. Does not cover dementia or healthy-user populations. The independent 2023 Cochrane stroke review found more non-fatal serious adverse events.)
Cochrane Library - Cerebrolysin for Acute Ischaemic Stroke, Ziganshina 2023 (CD007026.pub7)(2023 Cochrane update (7 RCTs, 1,773 people); no evidence of mortality benefit; potential increase in non-fatal serious adverse events (RR 2.39), no difference in total serious adverse events.)
For Better Science - Cerebrolysin: Sharmas, Masliah, and EVER Pharma (October 2024)(Investigative documentation of research misconduct findings, EVER Pharma funding ties, and the scope of cerebrolysin preclinical papers affected by the Masliah/Sharma data integrity crisis.)
BMC Neuroscience Retraction - Cerebrolysin Pick's disease paper (Masliah et al., PMID 40065222)(Retraction notice for a cerebrolysin preclinical paper retracted in 2025 due to fabricated/re-used figure panels. One of multiple Masliah cerebrolysin retractions.)
Cerebrolysin Fachinformation (Austrian SmPC, registration 1-21380, EVER Neuro Pharma GmbH, Stand March 2021), BASG medicines register(dose table)
Cerebrolysin Fachinformation (Austrian SmPC, registration 1-21380, EVER Neuro Pharma GmbH, Stand March 2021), BASG medicines register(dose table)
Cerebrolysin Fachinformation (Austrian SmPC, registration 1-21380, EVER Neuro Pharma GmbH, Stand March 2021), BASG medicines register(dose table)
Cerebrolysin Fachinformation (Austrian SmPC, registration 1-21380, EVER Neuro Pharma GmbH, Stand March 2021), BASG medicines register(dose table)
Cerebrolysin Fachinformation (Austrian SmPC, registration 1-21380, EVER Neuro Pharma GmbH, Stand March 2021), BASG medicines register(dose table)
Heiss WD et al. Stroke 2012;43(3):630-636. PMID 22282884. NCT00868283(dose table)
Ziganshina LE et al. Cochrane Database Syst Rev 2023;10:CD007026.pub7. PMC10565895(dose table)
Poon W et al. Neurol Sci 2020;41(2):281-293. PMID 31494820(dose table)
Muresanu DF et al. Neurol Sci 2020;41(5):1171-1181. PMID 31897941(dose table)
Funke et al. J Neural Transm Suppl 1998;53:385-398. PMID 9700674(dose table)
Huberman Lab, 'Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver', Oct 2024; third-party transcript segment 6148.9 to 6172.8 seconds(dose table)

Not medical advice. Grades reflect the evidence as of the date above and will change as data arrives. Reports from users are anecdote, not proof. Talk to a licensed clinician before you act on anything here.